TEVA PHARMACEUTICAL IND LTD
TEVANYSETrading Snapshot
- Day Range
- $39.64 โ $40.77
- 52-Week Range
- $6,160.00 โ $12,150.00
- Volume
- $3.48B
- Avg Volume
- $3.45B
- Shares Outstanding
- 1.16B
- Next Earnings
- Dec 8, 2026
Fundamentals Snapshot
- Annual Revenue
- $17.26B
- Last Q Revenue
- $4.14B
- P/E Ratio
- 64.5
- P/S Ratio
- 2.6x
- EPS (TTM)
- $0.60
- Dividend Yield
- โ
- Dilution (1yr)
- +3.5%
Why Investors Own TEVA
- โHigh-growth profile โ revenue up +34.2% YoY with expanding US Equity exposure.
- โHealthy economics โ 36% gross margin and 18% free-cash-flow margin.
- โNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
TEVA PHARMACEUTICAL IND LTD
TEVAAbout TEVA PHARMACEUTICAL IND LTD
Teva Pharmaceutical Industries Limited functions as a global pharmaceutical enterprise, involved in the conception, manufacturing, marketing, and provision of a broad spectrum of generic, specialty, and biopharmaceutical products throughout North America, Europe, and various international markets. The company's diverse product range includes sterile items, hormones, potent drugs, and cytotoxic agents, available in numerous forms like tablets, capsules, injectable solutions, inhalable preparations, liquids, transdermal patches, topical ointments, and creams. Additionally, Teva develops, produces, and sells active pharmaceutical ingredients (APIs). The firm prioritizes several key therapeutic domains: central nervous system disorders, pain management, respiratory ailments, and oncology. In the central nervous system sector, prominent products include Copaxone, intended for relapsing forms of multiple sclerosis; AJOVY, prescribed for preventing migraines; and AUSTEDO, which targets tardive dyskinesia and chorea linked to Huntington's disease. For respiratory conditions, Teva offers medications such as ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick, all designed to treat asthma and chronic obstructive pulmonary disease. The oncology portfolio features therapies like Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited is also engaged in a collaboration with MedinCell to advance and commercialize multiple long-acting injectable formulations, notably a risperidone suspension for individuals affected by schizophrenia. The company was established in 1901 and its primary headquarters are located in Tel Aviv-Yafo, Israel.
Otter Score Breakdown
How it's scoredFive components, each rated 1โ5โ and equally weighted (20%), averaged to a 0โ100 score:๐ Quality โ gross margin๐ Growth โ revenue YoYโ๏ธ Valuation โ P/S ratioโก Momentum โ 30-day price change๐ง Dilution โ 1-yr share issuance (buybacks score higher)Analyst Ratings
โLatest News & Updates
Teva's Branded Drugs Take Center Stage in Its Growth Strategy
Teva's branded drugs are driving stronger growth as Austedo, Ajovy and Uzedy gain momentum and its pipeline of new candidates expands.
Teva Pharmaceutical: 3 Numbers That Explain This Generic-Drug Turnaround
Forecasts call for Teva's branded drug portfolio to bring it $3.7 billion in revenue next year. At the same time, as it pivots toward high-margin drug products, Teva continues to reduce debt and improve its credit rating

Teva Continues Biosimilar Momentum with U.S. FDA Approval of DEGEVMAโข (denosumab-adet), a Biosimilar to Xgevaยฎ (denosumab)
TEL AVIV, Israel, and PARSIPPANY, N.J., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved DEGEVMAโข

QRG Capital Management Inc. Purchases 12,925 Shares of Teva Pharmaceutical Industries Ltd. $TEVA
QRG Capital Management Inc. grew its holdings in Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) by 17.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC).

Teva Eyes New Growth Phase After Securing Investment-Grade Ratings
Teva Pharmaceutical Industries (NYSE: TEVA) is planning for greater financial flexibility after receiving investment-grade ratings from all three major credit rating agencies, President and CEO Richard Francis said at th

Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ET
TEL AVIV, Israel and PARSIPPANY, N.J., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its third quarter 2026 financial r